Mode
Text Size
Log in / Sign up

Diabetic Macular Edema

Part of Diabetes

Subtypes of Diabetic Macular Edema

Diabetic Retinopathy 12

20 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Diabetic Macular Edema

107 trials tracked for Diabetic Macular Edema: 49 in phase 3 or 4 and 16 with published results. The most-cited published study has 293 citations.

107Trials tracked
49Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 4 15 Phase 3 34 Phase 2 47 Other / NA 11
  1. Phase 3 Treatment for CI-DME in Eyes With Very Good VA Study Completed · 293 cited
  2. Phase 3 Anti-VEGF Treatment for Prevention of PDR/DME Completed · 135 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema Completed · 135 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Completed · 135 cited
  5. Phase 3 Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease Completed · 106 cited
  6. Phase 3 DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME Completed · 81 cited
Show 44 more trials
  1. Phase 4 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Completed · 45 cited
  2. Phase 4 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed · 40 cited
  3. Phase 4 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed · 38 cited
  4. Phase 3 Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed · 37 cited
  5. Phase 4 Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA Completed · 36 cited
  6. Phase 4 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed · 28 cited
  7. Phase 3 Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) Completed · 14 cited
  8. Phase 3 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema Completed · 2 cited
  9. Phase 3 A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe Completed · 2 cited
  10. Phase 3 Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema Completed · 2 cited
  11. Phase 4 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed
  12. Phase 4 Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab Completed
  13. Phase 4 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab Completed
  14. Phase 4 Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium Completed
  15. Phase 4 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Completed
  16. Phase 4 A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema Completed
  17. Phase 4 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed
  18. Phase 4 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed
  19. Phase 4 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed
  20. Phase 4 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed
  21. Phase 3 Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone Completed
  22. Phase 3 A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients Completed
  23. Phase 3 Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye Completed
  24. Phase 3 Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME Completed
  25. Phase 3 Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  26. Phase 3 A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  27. Phase 3 To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  28. Phase 3 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Completed
  29. Phase 3 Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema Completed
  30. Phase 3 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Completed
  31. Phase 3 Effect of Ruboxistaurin on Clinically Significant Macular Edema Completed
  32. Phase 3 Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema Completed
  33. Phase 3 A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study Completed
  34. Phase 3 Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema Completed
  35. Phase 3 Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema Completed
  36. Phase 3 Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus Completed
  37. Phase 3 Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema Completed
  38. Phase 3 Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Completed
  39. Phase 3 Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) Completed
  40. Phase 3 Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study Completed
  41. Phase 3 Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema Completed
  42. Phase 3 Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  43. Phase 3 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Completed
  44. Phase 2 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) Completed

Showing the 50 most-cited and recently-updated of 107 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Diabetes

Related studies from across the Diabetes family.

Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy
Neurology Sys. Review
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy New research explores how inflammation drives nerve damage in diabetes
This narrative review explores the pathophysiology of diabetic peripheral neuropathy, focusing on how hyperglycemia, lipotoxicity, and intes…
Chronic high blood sugar causes more than just high glucose; it triggers a cycle of inflammation and immune stress that damages nerves.
Chronic hyperglycemia causes multi-level nerve damage across the peripheral, autonomic, and central nervous systems
Diabetes & Endocrinology Sys. Review
Chronic hyperglycemia causes multi-level nerve damage across the peripheral, autonomic, and central nervous systems Understanding how high blood sugar damages the entire nervous system in diabetes
This narrative review synthesizes how chronic hyperglycemia impacts the entire neuroaxis in patients with diabetes. It details metabolic and…
High blood sugar can damage nerves throughout the whole body. This affects your senses, movement, and internal organs.
Local antibiotic delivery systems increase healing rates in diabetic foot osteomyelitis compared with control groups in this meta-analysis
Infectious Disease Meta-analysis
Local antibiotic delivery systems increase healing rates in diabetic foot osteomyelitis compared with control groups in this meta-analysis Local Antibiotics May Boost Healing in Diabetic Foot Infections
This systematic review and meta-analysis evaluated local antibiotic delivery systems versus control groups for patients with diabetic foot o…
A new analysis suggests local antibiotic delivery may improve healing for diabetic foot bone infections, but more research is needed.
Antibiotic cement achieves 85.2% healing rate in diabetic foot osteomyelitis meta-analysis
Diabetes & Endocrinology Meta-analysis
Antibiotic cement achieves 85.2% healing rate in diabetic foot osteomyelitis meta-analysis Antibiotic cement may help heal diabetic foot infections without major surgery
A systematic review and meta-analysis of 82 patients with diabetic foot osteomyelitis found a weighted healing rate of 85.2% with antibiotic…
A meta-analysis suggests antibiotic-impregnated cement can heal diabetic foot osteomyelitis in most patients, though some still need surgery…
SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
Diabetes & Endocrinology Meta-analysis
SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c New review shows SGLT2 drugs raise DKA risk when blood sugar is high
This meta-analysis of observational and randomized trials found SGLT2 inhibitor use is associated with an increased risk of diabetic ketoaci…
A big review of many studies found that medicines for diabetes called SGLT2 inhibitors can increase the chance of a serious condition called…
Perioperative anti-VEGF injections improve vision and reduce bleeding in proliferative diabetic retinopathy
Ophthalmology Meta-analysis
Perioperative anti-VEGF injections improve vision and reduce bleeding in proliferative diabetic retinopathy Anti-VEGF injections before eye surgery improve vision and reduce bleeding in diabetic retinopathy
This network meta-analysis evaluated the timing of perioperative anti-VEGF injections for proliferative diabetic retinopathy. Results indica…
A network meta-analysis of 2,646 eyes found that perioperative anti-VEGF injections improved vision and reduced bleeding in patients with pr…
Scoping review maps burden of diabetic emergencies in African healthcare settings
Emergency Medicine Sys. Review
Scoping review maps burden of diabetic emergencies in African healthcare settings Diabetic emergencies in Africa show wide variation in rates and outcomes
This scoping review synthesizes data from 25 studies regarding diabetic emergencies in Africa. The authors report wide variation in reported…
A review of 25 studies finds diabetic emergencies in Africa vary widely, with high death rates and long hospital stays.
Review of 16 cases shows 25% mortality for pulmonary mucormycosis in DKA patients treated with amphotericin B
Rheumatology Meta-analysis
Review of 16 cases shows 25% mortality for pulmonary mucormycosis in DKA patients treated with amphotericin B Treatment for rare lung infection kills one in four patients with diabetic ketoacidosis
This case report and literature review synthesizes data from 16 patients with diabetic ketoacidosis complicated by invasive pulmonary mucorm…
A review of 16 patients found that one in four died from this rare lung infection. Early diagnosis and surgery are key.
Narrative review of salvianolic acids for kidney disease pharmacokinetics and anti-fibrotic activity
Drug Pipeline Sys. Review
Narrative review of salvianolic acids for kidney disease pharmacokinetics and anti-fibrotic activity Salvianolic Acids Show Potential for Kidney Disease Treatment
This narrative review synthesizes evidence on salvianolic acids A, B, and C for kidney conditions. It focuses on pharmacokinetic parameters,…
A review suggests salvianolic acids may help kidney conditions, though low absorption and fast metabolism limit current use.
Review of immune checkpoint inhibitor-associated diabetes mellitus in two patients
Allergy & Immunology Sys. Review
Review of immune checkpoint inhibitor-associated diabetes mellitus in two patients Diabetes Danger Lingers Months After Cancer Treatment Ends
This narrative review and case report describes two patients with immune checkpoint inhibitor-associated diabetes mellitus. The authors synt…
• Some patients develop dangerous diabetes long after stopping immunotherapy • Helps cancer survivors using newer immune-boosting drugs • St…
Pregabalin 300 or 600 mg/day significantly reduces pain in painful diabetic peripheral neuropathy versus placebo
Diabetes & Endocrinology RCT
Pregabalin 300 or 600 mg/day significantly reduces pain in painful diabetic peripheral neuropathy versus placebo Higher doses of pregabalin helped reduce pain scores for people with painful diabetic nerve problems compared to placebo
This randomized controlled trial enrolled 729 patients with painful diabetic peripheral neuropathy. Pregabalin doses of 300 mg/day and 600 m…
A study found that taking 300 or 600 mg of pregabalin daily lowered pain scores better than a fake pill. Lower doses did not work as well fo…
Ranibizumab plus PRP reduces residual disc neovascularization versus monotherapy in proliferative diabetic retinopathy
Rheumatology Cohort
Ranibizumab plus PRP reduces residual disc neovascularization versus monotherapy in proliferative diabetic retinopathy Adding Laser to Eye Injections Cuts Treatment Burden for Diabetic Eye Disease
This retrospective cohort study included 238 patients with proliferative diabetic retinopathy.
Combining injections with laser treatment for diabetic eye disease significantly reduces future procedures and complications while preservin…

Questions about Diabetic Macular Edema

How does brolucizumab compare to aflibercept for treating diabetic macular edema over time?

Brolucizumab and aflibercept both improve vision in diabetic macular edema, but brolucizumab may allow longer intervals between injections while carrying a higher risk of intraocular inflammation.

Full answer →
Are aflibercept biosimilars as safe and effective as the original drug for diabetic macular edema?

Yes, aflibercept biosimilars are as safe and effective as the original drug for diabetic macular edema, based on a systematic review and meta-analysis.

Full answer →
Does taking aflibercept every 8 weeks keep vision gains in diabetic macular edema?

Yes, taking aflibercept every 8 weeks maintains vision gains in diabetic macular edema, as shown in a 96-week trial where the 2 mg every 8 weeks regimen kept visual improvements comparable to extended dosing of 8 mg.

Full answer →
Is the new drug Pavblu approved for treating diabetic macular edema?

Yes, Pavblu (aflibercept) is FDA-approved for treating diabetic macular edema (DME).

Full answer →
Can suprachoroidal injections help improve vision in diabetic macular edema?

Yes, early studies show suprachoroidal injections of triamcinolone can improve vision and reduce swelling in diabetic macular edema, but more research is needed.

Full answer →
See all 5 questions about Diabetic Macular Edema →

All Diabetic Macular Edema Articles